Precision Optics Corporation, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended December 31, 2013 (fiscal 2014). Unaudited consolidated results include the company and its wholly owned subsidiaries. Precision Optics designs and manufactures medical optical instruments and, to a lesser extent, military and industrial products.
Financial performance
| Metric | Three months ended Dec. 31, 2013 | Six months ended Dec. 31, 2013 |
|---|---|---|
| Revenue | $1,007,717; up 102.1% year over year | $1,915,143; up 80.3% |
| Gross profit / margin | $205,416 / 20.4% (prior year: 16.1%) | $465,650 / 24.3% (prior year: 19.8%) |
| Operating loss | $252,453 | $463,174 |
| Net loss | $252,453, or $0.06 per share | $463,174, or $0.10 per share |
| Cash used in operating activities | The filing reports $302,589 for the quarter in MD&A | $449,622 |
Revenue growth reflected initial shipments of a new 3D surgical microscope adapter and higher unit sales of other products, including fiberscopes, scanning otoscopes, laryngoscopes, endocouplers, and micro optics. Higher volume contributed to improved gross margins, partly offset by product mix and nonrecurring startup manufacturing costs. Research and development expense declined year over year; selling, general and administrative expense rose, principally due to consulting, legal, selling, and stock-based compensation costs.
The six-month net loss improved from $1,264,578 in the prior-year period. Comparability is affected by prior-year unusual items: a $629,000 noncash provision for liquidated-damages claims and a $76,149 gain on settling accounts payable. The company recorded no income-tax provision in either period.
Liquidity, balance sheet, and capital
- At December 31, 2013, cash and cash equivalents were $577,588, accounts receivable $518,751, inventory $771,451, current assets $1,944,106, and current liabilities $657,072. Cash had declined from $1,034,587 at June 30, 2013.
- Net working capital was approximately $1.29 million. The company reported no indebtedness in default; it had previously retired its 10% senior convertible notes in 2012.
- Six-month investing cash outflow was $7,377, primarily for patent costs; no property-and-equipment purchases were reported. No financing cash flow occurred in the six months.
- Contractual operating lease commitments totaled $23,802, and open purchase-order commitments for fiscal 2014 were approximately $391,000.
- Common shares outstanding were 4,455,134. Approximately 3.382 million shares issuable under outstanding options and warrants were excluded from diluted loss-per-share calculations as antidilutive.
Outlook, risks, and notable disclosures
- Management anticipated continued revenue growth for the remainder of fiscal 2014, but gave no quantified guidance. It expected operating losses to continue until sales reach breakeven and profitable levels.
- Management described a $660,000 custom-endoscope order with deliveries accelerated from 16 months to 10 months, ongoing shipments against a separate $1.032 million order, and a $250,000 micro medical camera assembly order. Two development projects could move to production within three to six months, but volume purchase orders had not yet been obtained for those projects.
- Management cautioned that new-product order timing is unpredictable. Competition, price pressure, lengthy product development, and regulatory requirements may affect growth and costs. Customer concentration was significant: the three largest customers accounted for 20%, 20%, and 18% of six-month revenue, respectively.
- Disclosure controls and internal control over financial reporting were deemed ineffective at December 31, 2013. Management identified material weaknesses involving segregation of accounting duties and inventory valuation; remediation efforts were ongoing, and management could not guarantee successful remediation.
- The company reported no known pending or threatened litigation expected to materially affect operations or finances, and no material changes to the risk factors in its prior annual report. It reported no off-balance-sheet arrangements.
Investor verification points
- Confirm subsequent revenue, margins, and cash burn, including whether higher sales translate into sustainable profitability and adequate liquidity.
- Track fulfillment and collection of the disclosed customer orders, and whether development projects secure volume-production orders.
- Assess customer concentration and potential share dilution from outstanding options and warrants.
- Review progress in remediating the disclosed material weaknesses and whether controls remain effective.
- Reconcile the quarter-specific operating cash-use figure in MD&A ($302,589) with the six-month cash flow statement ($449,622) and subsequent cash balances.